Revolutionizing plasma cell disorder diagnostics with mass spectrometry

Angela Dispenzieri, MD, Professor of Medicine, Division of Hematology, Department of Internal Medicine, Mayo Clinic, discusses the use of mass spectrometry for plasma cell disorder diagnostics. Mass spectrometry of monoclonal proteins is transforming plasma cell disorder diagnostics by enhancing sensitivity and specificity beyond traditional immunofixation. This innovative approach provides detailed fingerprinting of myeloma and amyloid proteins, crucial in the era of therapeutic monoclonal antibodies. With the ability to accurately identify and monitor proteins, mass spectrometry offers revolutionary potential in diagnosing and managing plasma cell disorders, promising more precise treatment outcomes for patients.